Arvinas and Pfizer have entered an international partnership to jointly develop and market the former’s investigational therapy, ARV-471, for breast cancer.
New Haven, Conn.-based Arvinas expanded an ongoing licensing deal with Genentech. The agreement is to develop new drugs using Arvinas’ PROTAC technology. The original deal was inked in October 2015.
Arvinas, a private biotechnology company creating a new class of drugs based on protein degradation, has appointed Dr. John Houston as President of Research and Development and Chief Scientific Officer to lead discovery research, translational research an